View Future GrowthVaccinex 過去の業績過去 基準チェック /06Vaccinexは8%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで30%毎年増加している。売上は成長しており、年平均5.4%の割合である。主要情報7.98%収益成長率79.67%EPS成長率Biotechs 業界の成長17.04%収益成長率5.44%株主資本利益率n/aネット・マージン-3,100.50%前回の決算情報31 Dec 2024最近の業績更新Full year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022) Apr 02First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021) Aug 16すべての更新を表示Recent updatesVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer At Asco Annual MeetingMay 27Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)Apr 21Vaccinex, Inc. announced delayed annual 10-K filingApr 02Vaccinex, Inc. Files Form 15Mar 28Vaccinex, Inc. Intends to Delist Common Stock from NasdaqMar 08Vaccinex, Inc.(OTCPK:VCNX) dropped from S&P TMI IndexDec 20Vaccinex, Inc.(OTCPK:VCNX) dropped from NASDAQ Composite IndexDec 19Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.Nov 15+ 1 more updateVaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, SpainNov 01Vaccinex Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)Oct 10New major risk - Financial position Aug 16Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development PartnershipAug 14Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S DiseaseJul 31Insufficient new directors Jul 02Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s DiseaseJun 08Vaccinex, Inc. announced that it has received $1.75 million in fundingApr 13+ 1 more updateVaccinex, Inc. announced delayed annual 10-K filingApr 03+ 1 more updateFull year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022) Apr 02Vaccinex, Inc. announced that it expects to receive $1.49961 million in fundingMar 28Vaccinex, Inc. has filed a Follow-on Equity Offering.Mar 27Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital MarketFeb 15Vaccinex, Inc. announced that it expects to receive $3.700126 million in fundingFeb 07New major risk - Market cap size Dec 01New major risk - Financial position Nov 15Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual MeetingNov 01Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOct 29Vaccinex Receives Non-Compliance Notice From NasdaqOct 14Vaccinex's Next Generation ActivMAb®? Technology Published in mAbsSep 29Vaccinex, Inc. to Present Update on PDAC/Pepinemab StudySep 28Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and CancerSep 27Vaccinex, Inc. Provides Nasdaq Compliance UpdateSep 23Vaccinex, Inc. announced that it has received $0.65 million in fundingAug 23New major risk - Financial position Aug 15New minor risk - Share price stability Jun 19Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)May 31Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co.May 16Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface OncologyJan 10Insufficient new directors Nov 16Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of CancerNov 11Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid RequirementOct 12First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021) Aug 16Insufficient new directors Apr 27Vaccinex, Inc., Annual General Meeting, May 12, 2022Apr 06Vaccinex, Inc. announced that it expects to receive $6.599997 million in fundingJan 28Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck CancerJan 27Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety AnalysisJan 05Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech SummitSep 20Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use DebtAug 17Price target decreased to US$7.00 Jul 19Vaccinex, Inc.(NasdaqCM:VCNX) dropped from Russell Microcap Value IndexJun 28+ 1 more updateVaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s DiseaseJun 09Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDAMay 19収支内訳Vaccinex の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:VCNX 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 241-197030 Sep 240-197-330 Jun 240-187031 Mar 240-197031 Dec 231-207030 Sep 231-227330 Jun 231-227031 Mar 231-206031 Dec 220-206030 Sep 220-1961030 Jun 220-206031 Mar 220-206031 Dec 211-226030 Sep 211-247-1730 Jun 211-287031 Mar 211-287031 Dec 201-297030 Sep 201-2971730 Jun 200-287031 Mar 200-307-731 Dec 191-327030 Sep 191-346730 Jun 191-3361231 Mar 191-3152531 Dec 181-3052230 Sep 181-2442030 Jun 180-2441931 Mar 180-2351731 Dec 170-2241731 Dec 160-26416質の高い収益: VCNXは現在利益が出ていません。利益率の向上: VCNXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VCNXの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: VCNXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: VCNXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 40.2% ) と比較することは困難です。株主資本利益率高いROE: VCNXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 10:08終値2026/05/01 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vaccinex, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Thomas ShraderBTIGMatthew KaplanLadenburg Thalmann & CompanyLeland GershellOppenheimer & Co. Inc.
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer At Asco Annual MeetingMay 27
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)Apr 21
Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.Nov 15+ 1 more update
Vaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, SpainNov 01
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development PartnershipAug 14
Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S DiseaseJul 31
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s DiseaseJun 08
Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital MarketFeb 15
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual MeetingNov 01
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOct 29
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and CancerSep 27
Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)May 31
Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co.May 16
Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface OncologyJan 10
Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of CancerNov 11
Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid RequirementOct 12
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck CancerJan 27
Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety AnalysisJan 05
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech SummitSep 20
Vaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s DiseaseJun 09
Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDAMay 19
